As of November 15, 2026, Annovis Bio, Inc. is a publicly traded company (NYSE: ANVS); its largest reported holder is Highbridge, with 6.1% on Schedule 13G of August 14, 2026. The largest insider holding is Michael Hoffman, a director, with 8,588,240 shares (13.8% of shares outstanding), per Form 4 of November 6, 2026. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13G, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Annovis Bio, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Annovis Bio, Inc. a real, registered company?
- Annovis Bio, Inc. files with the SEC under CIK 1477845 (its SEC filings).
- Its shares are listed under the ticker ANVS on NYSE (SEC company record).
- Incorporated in Delaware; business address in Malvern, Pennsylvania, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Annovis Bio, Inc. in our court records and SEC 8-K records (as of 2026-11-15).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Highbridge (filed 2026-08-14).
Who are Annovis Bio, Inc.'s owners and officers?
Annovis Bio, Inc.: incorporated in Delaware; business address in Malvern, Pennsylvania; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-10-15).
Officers and directors, each with the role and the filing that names them:
- : Executive Officer, Director (Form D, 2023-04-25)
- : Director (Form D, 2023-04-25)
- : Director (Form D, 2023-04-25)
- : Director (Form D, 2023-04-25)
- : Director (Form D, 2023-04-25)
- : Executive Officer (Form D, 2023-04-25)
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-10-15 | Empery Asset Management, LP | 4.99% |
| Schedule 13G, 2026-08-14 | Highbridge Capital Management, LLC | 6.1% |
| Schedule 13G, 2026-07-29 | Empery Asset Management, LP | 5.64% |
Questions about who owns Annovis Bio, Inc.
Who owns Annovis Bio, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Annovis Bio, Inc.: Highbridge Capital Management, LLC (6.1%, Schedule 13G, filed 2026-08-14).
When did Highbridge Capital Management, LLC buy into Annovis Bio, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Highbridge Capital Management, LLC on this page is the Schedule 13G, filed 2026-08-14, reporting 6.1%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 3 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Annovis Bio, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Annovis Bio, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Annovis Bio, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Annovis Bio, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , a director: 8,588,240 shares (13.8% of shares outstanding), 8,364,883 held directly and 223,357 indirectly (Form 4, 2026-11-06).
- , the chief executive and president: 1,212,020 shares (2.0% of shares outstanding) (Form 4, 2025-11-12).
- , a director: 13,709 shares (0.02% of shares outstanding) (Form 4, 2025-11-12).
- , a director: 9,305 shares (0.02% of shares outstanding) (Form 4, 2025-06-11).
- , the president and finance: 500 shares (0.00% of shares outstanding) (Form 4, 2025-06-18).
Shares outstanding: 62,022,520 as of 2026-11-13, from the company's latest SEC cover page.
How much has Annovis Bio, Inc. raised?
| Filed | Sold | Offered |
|---|---|---|
| Form D, 2023-04-25 | $1.06M | $1.06M |
Keep reading
More on Annovis Bio, Inc. and the records around it.
Companies that share a holder
- Empery Asset Management, LP also filed stake reports on 21 other companies: Dyadic International Inc. (Oct 2026), Femasys Inc. (Oct 2026), Clene Inc. (Oct 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/annovis-bio